A Phenomics Australia case study
Phenomics Australia has enabled the identification of a promising cancer therapeutic to treat Ovarian cancer.
The challenge:
Intrinsic and acquired drug resistance are fundamental barriers to the cure of High-Grade Serous Ovarian Cancer (HGSOC).
The solution:
Identify new therapies targeting this disease.
The future:
CX-5461 is a promising therapy for the treatment of High-Grade Serous Ovarian Cancer.
The challenge: Intrinsic and acquired drug resistance are fundamental barriers to the cure of High-Grade Serous Ovarian Cancer (HGSOC).
Ovarian cancer (OVCA) is the major cause of death from gynaecological cancers. The high-grade serous ovarian cancer (HGSOC) subtype accounts for 70–80% of OVCA deaths and overall survival has not changed for several decades.
Intrinsic and acquired drug resistance represent fundamental barriers to the cure of HGSOC resulting in patient mortality. This highlights the need to identify new therapies targeting this disease.
The solution: Identify new therapies targeting this disease.
This study, supported by Phenomics Australia, identifies potential targets whose inhibition can enhance the efficacy of CX-5461 in treating this disease.
The future: CX-5461 is a promising therapy for the treatment of High-Grade Serous Ovarian Cancer.
This study, shows promise for CX-5461, a cancer therapeutic in early phase clinical trials, in treating HGSOC.
References:
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
